Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Circulation|May 5, 2021
Evidence-Based Assessment of Genes in Dilated CardiomyopathyElizabeth Jordan, Laiken Peterson, Tomohiko Ai, et al.
Circulation|October 7, 2022
Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational StudyAlessio Gasperetti, Richard T Carrick, Sarah Costa, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 13, 2021
The genetic architecture of Plakophilin 2 cardiomyopathyAnnika M Dries, Anna Kirillova, Chloe M Reuter, et al.
European Journal of Heart Failure|July 24, 2012
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathyPaul A van der Zwaag, Ingrid A W van Rijsingen, Angeliki Asimaki, et al.
Human Mutation|November 6, 2022
KBTBD13 is a novel cardiomyopathy geneJosine M de Winter, Karlijn Bouman, Joshua Strom, et al.
Genome Medicine|September 18, 2023
Identification of novel genetic risk factors of dilated cardiomyopathy: from canine to humanJulia E Niskanen, Åsa Ohlsson, Ingrid Ljungvall, et al.
European Heart Journal|October 27, 2015
Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriersGodelieve R F Claes, Florence H J van Tienen, Patrick Lindsey, et al.
Circulation. Cardiovascular Genetics|August 10, 2017
Lamin A/C-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder MutationEdgar T Hoorntje, Ilse A Bollen, Daniela Q Barge-Schaapveld, et al.
Heart Rhythm|November 3, 2019
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summaryJeffrey A Towbin, William J McKenna, Dominic J Abrams, et al.
Circulation. Genomic and Precision Medicine|May 22, 2019
Mortality Risk Associated With Truncating Founder Mutations in TitinMark Jansen, Annette F Baas, Karin Y van Spaendonck-Zwarts, et al.
Pageof 21